Burton-on-Trent-based specialist medicines supplier Clinigen (CLIN) looks to be performing well after the company reported that it looks on course to beat forecasts for earnings this year. There were no specific numbers available, but analysts reacted with earnings upgrades of between 5 per cent and 10 per cent.
There was apparently a small contribution to sales late on in the year from Clinigen's newly acquired Cardioxane oncology product, but the real growth was in the global access business, where full-year sales are six times higher on a like-for-like basis. Lower administration costs will also help cash profits. Clinigen reports its full-year results on Wednesday 25 September 2013.
